Longtime Slashdot reader schwit1 shares a report from Autoblog: For years, the Chinese auto industry has employed a hostile price war to kneecap global competitors. Armed with massive state subsidies, cheap raw materials, and an aggressive "scale-first" business model, Chinese automakers flooded the market with electric vehicles priced so low that legacy manufacturers stood no chance to compete. How did they do it? Simple, they couldn't. They did it anyway. Reports from CarNewsChina show that Chinese automakers have been selling vehicles at a loss until a recent law passed by the Chinese government banned below-cost sales of new vehicles. During the ongoing sales slump in China caused by rolled-back subsidies and direct government intervention banning below-cost sales, the truth behind the rapid expansion of the Chinese auto industry has been exposed. "By the first quarter of 2026, China captured 32 percent of the global auto market, with its New Energy Vehicles (NEVs) controlling an incredible 61 percent of global share," the report notes. Yet that dominance has come at a steep cost: throughout 2025, "the profit margin for China's auto industry plunged to 4.4 percent and dropped further to a historic low of 3.2 percent in early 2026." "Gross profit, not net profit, per vehicle, plummeted to a mere $2,000. We can expect the net figure to be loss-making." Autoblog adds: "Data shows over 70 percent of Chinese car sales were loss-making. This left more than half of the country's auto industry in the red. Great Wall Motor (GWM) even saw net profits drop 17 percent despite steady revenue growth." China's EV price war has now hit a wall. New regulations are discouraging below-cost sales, rising material costs are forcing automakers to cut discounts and raise prices, and reduced tax incentives are weakening domestic demand. To sustain growth, manufacturers are increasingly turning to exports.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Bloomberg: While traditional hotspots in the region such as Thailand, South Korea and Malaysia focus on services such as cosmetic surgery, IVF or physicals, China is trying to differentiate itself by providing some of the world's most advanced procedures. "There are two reasons why a patient travels for medical treatments: availability of advanced treatments and price," said Victor Cao, operations director of Joyful Medical, an agency in Shanghai that connects international patients to advanced cancer therapies in China. "Chinese people used to travel overseas for treatments that were not available at home, but now tables have turned." As expanding visa-free policies eased travel in the past year or so, videos are proliferating on social media of foreigners recounting their positive experiences of treatment in China, usually for consumer procedures like acupuncture and tooth scaling. But one treatment that's more quietly gaining traction is CAR-T, among the most promising breakthroughs in oncology but unavailable in most countries, or extremely costly. The process sees doctors collect T cells from the patient's blood then modify them in a lab to produce a special receptor, CAR, that can bind to a specific protein on cancer cells. These engineered cells are then multiplied into large numbers and infused back into the patient. The CAR-T cells seek out cancer cells carrying the target antigen and kill them. In the US, one single infusion can cost between $300,000 to $475,000, according to the American Cancer Society. In China, the equivalent costs about $150,000 to $180,000, and it could get even cheaper -- its drug regulator recently accepted a marketing application for a therapy aimed to be priced below 300,000 yuan ($44,000). China's medical tourism market remains in its infancy. Lecheng International Medical Tourism Pilot Zone in Hainan, which was designated as the country's only special medical zone in 2013, treated just a few thousand foreign medical tourists last year, compared to hundreds of thousands of domestic patients who visited. There, patients can access advanced drugs, devices, and therapies approved in other countries but not elsewhere in mainland China. But China is pushing to upgrade its economy and reshape its global image from just a manufacturing hub into a provider of high-value services, and demand for medical tourism is surging. Globally, the market is estimated at around $34 billion and expected to reach $126 billion by 2035, according to San Francisco-based Grand View Research. Meanwhile, China's sector is projected to grow from $1.3 billion in 2025 to $3.4 billion by 2035, according to New York-based firm Market Research Future. "The patients chose China for something they can't get at home," said Shi Haoying, the group's founder and chief executive officer. "I think the growing attention to medical tourism to China is the inevitable result of long-term accumulation and development in many areas, such as growing medical technologies, quality of service and cost-effectiveness." Jeroen Groenewegen-Lau, an analyst at the Mercator Institute for China Studies, added: "Many new treatments, including in very advanced areas, are made in China but too advanced for the state of its healthcare system and the ability of its patients to pay for these things. It's in China's interest to integrate into the international system."

Read more of this story at Slashdot.

An anonymous reader quotes a report from Politico: China was likely behind an online influence operation to sway U.S. perceptions of artificial intelligence technology and reshape the debate in Washington around the infrastructure needed to support it, according to research from OpenAI published Wednesday. OpenAI said it caught the influence campaign because China-backed operatives were using ChatGPT to create content for the social media campaign. [...] OpenAI's researchers identified two clusters of ChatGPT users "likely originating from China" who used the AI chatbot to generate social media content "in support of apparent covert influence operations" promoting certain narratives about AI. This includes claims that data center build-outs are raising electricity costs for the average American family and that President Donald Trump has weaponized tariffs to keep the U.S. ahead in the global tech race. These accounts have since been banned, the report said. One cluster of users asked ChatGPT to generate images and comments pushing these narratives. These comments were then posted on social media by "batches of accounts" posing as Americans, [said Ben Nimmo, principal investigator of intelligence and investigations at OpenAI]. Another cluster identified by researchers used AI to generate social media content criticizing the Trump administration's tariffs as an attempt to "dominate technological competition." Prompts used for this campaign were submitted in Simplified Chinese and asked that AI-generated content not include Chinese President Xi Jinping and focus solely on Trump -- a possible tell that China was behind the operation, according to the report. Nimmo said that the influence campaign amplified existing public backlash in the U.S. against the creation of new AI data centers, which has resulted in dozens of proposed moratoriums at the local, state and national level. "Neither campaign appears to have gained much authentic engagement," Nimmo said. "They're important for what they reveal about the intentions of influence operators from China, and the narratives they're testing and seeking to amplify, but not for the impact."

Read more of this story at Slashdot.

The Pentagon has added Alibaba, BYD, Baidu, Unitree, and other Chinese companies to its list of firms it says support China's military, barring them from U.S. defense contracts. The companies and China's embassy deny the allegations. The Associated Press reports: Created in 2021 by a congressional mandate, the list (PDF) seeks to identify Chinese companies that the Pentagon considers to have links to the Chinese military -- not only those directly controlled by the Chinese military and security forces but also those contributing to the country's defense industrial base. When updating the list last year, the Pentagon said the Chinese military sought to acquire advanced technologies and expertise developed by Chinese companies, universities and research programs that "appear to be civilian entities." The Chinese Embassy on Monday accused the U.S. of "overstretching the concept of national security and making discriminatory lists to go after Chinese companies." It said Chinese companies observe the laws and regulations of the countries where they do business. "The U.S. should stop its wrong practice and create a fair, just and non-discriminatory environment for Chinese companies," the embassy said in a statement. [...] The Chinese Embassy on Monday accused the U.S. of "overstretching the concept of national security and making discriminatory lists to go after Chinese companies." It said Chinese companies observe the laws and regulations of the countries where they do business. "The U.S. should stop its wrong practice and create a fair, just and non-discriminatory environment for Chinese companies," the embassy said in a statement.

Read more of this story at Slashdot.